Compare multi-agent consensus ratings, forecast paths, AI price targets, expected return, fundamentals, analyst disagreement, risks, and the investment thesis across short- and long-term horizons.

AZN.LSE

AstraZeneca

Healthcare | Drug Manufacturers - General

British-Swedish multinational pharmaceutical and biotechnology company developing treatments for cancer, cardiovascular, and respiratory diseases.

Flagship Insight

Why the Market Misprices This Biopharma Giant's Hidden Supply Chain Arbitrage

Input reports show a sharp divergence regarding this biopharma asset. While high consensus exists on its core oncology dominance, opinions clash over massive domestic manufacturing capital expenditures and regulatory pricing pressures. The primary driver remains pipeline execution, while geopolitical supply chain decoupling represents the ultimate downside risk.

Forecast TimelineUpdated On Jul 03 2026

AstraZeneca (AZN) Stock Forecast and AI Rating

Recommendation

Small Buy

Open a small position; wait before adding more.

2027

1-Year

BUY

15,468 GBX

+7.0%

+25% IF INCL. DIVS

2029

3-Year

N/A

18,235 GBX

+46%

2031

5-Year

BUY

21,312 GBX

+47%

+89% IF INCL. DIVS

LATEST DEEP FORECAST ANALYSIS BY iPULSE AI ENGINE | Jul 05, 2026

Visionary, Superintelligence, Insider, Strategist, Value Seeker, Vulture, Whistleblower, and more.

Elon Musk (Visionary), Superintelligence (Anthropologist), Machiavelli (Insider), Ray Dalio (Strategist), Warren Buffett (Value Purist), Michael Burry (Vulture), Sherlock Holmes (Whistleblower).

Research support only. We don't give financial advice.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Grok

Investment Thesis Takeaway

Expert LanguageExpert Quant Language

Explained Simply

Interactive forecast chart

Expert Language

Explained Simply

This biopharma asset represents a highly resilient, cash-generative compounder navigating a challenging stagflationary macro regime. The core investment thesis centers on its structural oncology dominance and rare disease pricing power, which effectively insulate operating cash flows from inflationary pressures and economic downturns. However, a sharp analytical divergence exists regarding the capital intensity of its massive domestic manufacturing reshoring and its geopolitical exposure. While some perspectives view these heavy capital expenditures as a defensive tax that compresses near-term free cash flow, others identify them as a critical sovereign moat that secures long-term supply chain integrity in a fragmenting global landscape.

Key insights

Core oncology and rare disease portfolios provide highly inelastic demand and robust pricing power, shielding margins from inflationary shocks.
Massive capital expenditures for domestic manufacturing reshoring temporarily depress free cash flow margins but secure long-term sovereign alignment.
Geopolitical decoupling mandates introduce supply chain transition risks and R&D cost inflation, particularly regarding Asian partnerships.
Advanced computational biology and machine learning integration structurally accelerate pipeline development timelines and improve clinical success probabilities.
Regulatory pricing frameworks in key Western markets impose a persistent ceiling on terminal margins, limiting multiple expansion.
Pristine balance sheet leverage provides substantial downside protection and counter-cyclical acquisition optionality in a tight liquidity environment.

Preparing your access...

AI Consensus

AI Opinions

Company Profile

AstraZeneca quarterly forecast scenarios

One row per forecast quarter. Asset scenario targets are shown in GBX; benchmark values are shown in USD.

Quarterly Bear Case, Base Case, Bull Case, and S&P 500 benchmark forecasts for AstraZeneca, including GBP/USD currency conversion forecasts.
Quarter	Forecast date	Bear Case (GBX)	Base Case (GBX)	Bull Case (GBX)	S&P 500 benchmark (USD)	Currency conversion forecast (GBP/USD)
Quarter 1+3M	Oct 03, 2026	12,866 GBX	14,637 GBX	15,034 GBX	$736.09	1.3145
Quarter 2+6M	Jan 03, 2027	11,837 GBX	14,834 GBX	15,485 GBX	$724.14	1.3027
Quarter 3+9M	Apr 03, 2027	11,126 GBX	15,125 GBX	15,795 GBX	$713.57	1.3029
Quarter 4+1Y	Jul 03, 2027	10,570 GBX	15,311 GBX	16,427 GBX	$723.38	1.3004
Quarter 5+15M	Oct 03, 2027	9,830 GBX	15,468 GBX	16,432 GBX	$716.61	1.2887
Quarter 6+18M	Jan 03, 2028	9,437 GBX	15,902 GBX	17,089 GBX	$738.34	1.2831
Quarter 7+21M	Apr 03, 2028	9,248 GBX	16,209 GBX	17,579 GBX	$746.91	1.2832
Quarter 8+2Y	Jul 03, 2028	9,711 GBX	16,547 GBX	18,634 GBX	$771.93	1.2856
Quarter 9+27M	Oct 03, 2028	9,128 GBX	16,826 GBX	19,193 GBX	$782.73	1.2831
Quarter 10+30M	Jan 03, 2029	8,672 GBX	17,196 GBX	19,961 GBX	$807.31	1.2755
Quarter 11+33M	Apr 03, 2029	8,498 GBX	17,649 GBX	20,959 GBX	$822.72	1.2791
Quarter 12+3Y	Jul 03, 2029	8,158 GBX	17,949 GBX	21,588 GBX	$846.10	1.2810
Quarter 13+39M	Oct 03, 2029	8,485 GBX	18,235 GBX	22,019 GBX	$852.53	1.2818
Quarter 14+42M	Jan 03, 2030	8,230 GBX	18,806 GBX	23,120 GBX	$882.91	1.2797
Quarter 15+45M	Apr 03, 2030	8,230 GBX	18,946 GBX	24,045 GBX	$900.46	1.2774
Quarter 16+4Y	Jul 03, 2030	8,477 GBX	19,458 GBX	25,488 GBX	$922.67	1.2737
Quarter 17+51M	Oct 03, 2030	8,307 GBX	19,822 GBX	26,252 GBX	$935.91	1.2680
Quarter 18+54M	Jan 03, 2031	8,474 GBX	20,498 GBX	27,303 GBX	$952.30	1.2716
Quarter 19+57M	Apr 03, 2031	8,558 GBX	20,736 GBX	28,122 GBX	$976.28	1.2700
Quarter 20+5Y	Jul 03, 2031	8,387 GBX	21,312 GBX	29,246 GBX	$1,002	1.2674

Alpha Gap and Advisor Disagreement

Alpha Gap

The core information gap lies in the market's mispricing of the company's geopolitical supply chain strategy and its technological transition. While the crowd views massive capital commitments to domestic manufacturing reshoring as a near-term drag on margins, this proactive spending actually converts geopolitical risk into a proprietary competitive moat. Less capitalized peers will suffer severe supply chain disruptions, while this company secures sovereign-compliant capacity. Furthermore, the market systematically underestimates the non-linear efficiency gains from the early integration of artificial intelligence and computational biology into the research and development pipeline. Rather than a legacy pharmaceutical manufacturer, the company is transitioning into a highly efficient biological platform, a structural shift that traditional valuation models fail to capture.

Advisor Disagreement

The primary disagreement across the reports centers on the long-term impact of the company's massive capital expenditure program. One perspective views the multi-billion-dollar domestic manufacturing reshoring commitment as a defensive, politically forced tax that will severely compress free cash flow and destroy shareholder value. Conversely, another perspective argues that this capital intensity is a visionary investment that secures supply chain sovereignty and builds an impenetrable geopolitical moat. Additional disagreements emerge regarding the timeline and probability of success for the company's oral metabolic pipeline.

Financial Reviews by iPulse AI

Earnings and financials

The company is currently showing exceptional financial strength, with revenues growing steadily and net income surging significantly. This strong performance is driven by the massive success of its cancer and rare disease treatments, which remain in high demand regardless of economic conditions. The reports generally agree that the company's ability to generate cash is highly reliable, making it a safe haven during periods of high inflation. However, there is a clear disagreement regarding the future outlook. Some analysts believe this cash-printing machine will continue to accelerate as new drugs are launched. In contrast, others warn that upcoming price cuts mandated by governments and the loss of patents on older drugs will soon eat into profits, potentially leading to a sharp slowdown in earnings growth over the next few years.

Profitability and margins

The company boasts exceptionally high profit margins, driven by its ability to set premium prices for life-saving cancer and rare disease treatments. The reports agree that these strong margins protect the company from rising costs of raw materials and energy. However, there is a major clash over where margins are headed next. Optimistic views suggest that margins will expand even further as high-value new treatments scale up and artificial intelligence makes drug discovery cheaper. Conversely, cautious perspectives warn of a looming margin squeeze. They argue that government-enforced price caps in the United States and the heavy costs of building new factories will inevitably drag profit margins down from their current peak levels, making the stock look expensive at its current valuation.

Balance sheet and leverage

The company's balance sheet is widely considered a financial fortress, characterized by low debt levels and excellent ability to cover interest payments. The reports highly agree that this financial safety net protects the company from rising interest rates and tight credit markets. This strong position gives the company the unique ability to fund its own massive research projects without needing to borrow expensive money. Furthermore, it provides the firepower to acquire smaller, struggling biotechnology companies at bargain prices during economic downturns. While there is minor disagreement over how much new debt might be needed to fund the company's massive Western factory expansion, the overall consensus is that the balance sheet is incredibly safe and acts as a solid anchor for long-term investors.

Capex and investment intensity

The company is spending heavily on research and development, alongside a massive multi-billion-dollar push to build new manufacturing facilities in Western countries. The reports agree that this heavy spending is necessary to move supply chains away from politically risky regions and comply with new trade regulations. However, opinions differ on what this means for investors. Some views suggest this aggressive investment is a brilliant move that secures the company's future independence and protects it from geopolitical conflicts. On the other hand, some analysts worry that this massive spending is a forced political tax that will drain the company's cash reserves, increase depreciation costs, and hurt short-term returns. Ultimately, while the spending builds a strong safety shield, it will likely limit the cash available for immediate share buybacks.